Tango Therapeutics announced an expansion of its management team with the promotion of Alan Huang, Ph.D., to chief scientific officer and the addition of Charles Davis, Ph.D., as senior vice president, pharmaceutical sciences.

“We are thrilled to have Alan leading our scientific efforts. His wealth of experience in oncology research and his strategic approach to building Tango’s target and drug discovery platform will help us in our drive to get important new drugs to the patients who need them most,” said Barbara Weber, M.D., Tango’s chief executive officer. “I’m also delighted to welcome Charles to lead our pharmaceutical sciences capabilities. His expertise will be vital as we build a fully integrated biopharma company with capabilities from target discovery through clinical development and commercialization.”

Alan Huang, Ph.D., joined Tango Therapeutics as senior vice president, head of biology, after serving as a consultant at Third Rock Ventures, where he played a leading role in the creation and launch of Tango. He is an author on more than 30 peer-reviewed publications and holds nearly 20 patents.

“I’m excited to be expanding my role at Tango at a time when we’ve validated our approach and we’re moving ahead with a clear sense of purpose to produce therapeutic breakthroughs for patients,” Alan said.

Charles Davis, Ph.D., comes to Tango from the Novartis Institutes for BioMedical Research, where he served as vice president, PK sciences. Before joining Novartis, Charles spent more than 20 years at GlaxoSmithKline, where he served on the leadership teams of three of GSK’s Centers of Excellence in Drug Discovery

“Tango’s science is truly exciting,” Charles said. “This is a dynamic team and I’m glad to come aboard as we work together to build on our strong scientific foundation to advance multiple programs to the clinic.”